Abstract
We read with great interest the article by Sohn and associates, “Changes in Aqueous Concentrations of Various Cytokines after Intravitreal Triamcinolone versus Bevacizumb for Diabetic Macular Edema.” 1 Sohn H.J. Han D.H. Kim I.T. et al. Changes in aqueous concentrations of various cytokines after intravitreal triamcinolone versus bevacizumab for diabetic macular edema. Am J Ophthalmol. 2011; 152: 686-694 Abstract Full Text Full Text PDF PubMed Scopus (214) Google Scholar They reported that only aqueous vascular endothelial growth factor (VEGF) was decreased significantly after intravitreal bevacizumab (IVB) treatment, but that aqueous levels of interleukin (IL)-6, IL-8, interferon-induced protein-10, monocyte chemotactic protein (MCP)-1, and platelet-derived growth factor-AA were not affected by IVB treatment. 1 Sohn H.J. Han D.H. Kim I.T. et al. Changes in aqueous concentrations of various cytokines after intravitreal triamcinolone versus bevacizumab for diabetic macular edema. Am J Ophthalmol. 2011; 152: 686-694 Abstract Full Text Full Text PDF PubMed Scopus (214) Google Scholar Previously, Funk and associates also reported that IVB resulted in a significant decrease of VEGF and that all other cytokines, including IL-8 and MCP-1, were not affected in patients with diabetic macular edema (DME). 2 Funk M. Schmidinger G. Maar N. et al. Angiogenic and inflammatory markers in the intraocular fluid of eyes with diabetic macular edema and influence of therapy with bevacizumab. Retina. 2010; 30: 1412-1419 Crossref PubMed Scopus (99) Google Scholar Changes in Aqueous Concentrations of Various Cytokines After Intravitreal Triamcinolone Versus Bevacizumab for Diabetic Macular EdemaAmerican Journal of OphthalmologyVol. 152Issue 4PreviewTo investigate the changes in aqueous inflammatory and angiogenic cytokine levels after intravitreal injection of triamcinolone or bevacizumab for reducing foveal thickness in diabetic macular edema (DME). Full-Text PDF ReplyAmerican Journal of OphthalmologyVol. 153Issue 2PreviewWe appreciate the comments of Lee and Cho regarding short-term changes of aqueous inflammatory cytokines after intravitreal bevacizumab (IVB) for diabetic macular edema, and their remarks about possible acute alteration of associated cytokines after IVB are worth considering. Full-Text PDF
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
